Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INE963 in Patients with Malaria

The primary objective of this study is to evaluate the **safety** and **tolerability** of INE963, a novel compound, in the treatment of **malaria**. This is clinically relevant as ensuring the safety and tolerability of new treatments is crucial for patient health and the successful development of effective therapies for malaria, a disease with significant global health impact.

The clinical trial involves participants diagnosed with **malaria**. The study population includes both male and female subjects, with an age range categorized as 3, which typically corresponds to adults. The general health status of the participants is not specified, and the sponsor has not provided the total number of participants involved in the trial. The selection process for the trial population is not detailed, and there is no information regarding specific lifestyle considerations such as diet, physical activity, or habits. The trial does not focus on a vulnerable population, and no significant inclusion or exclusion criteria have been highlighted by the sponsor.

The clinical trial is designed to evaluate the **safety**, tolerability, metabolism, and elimination of a new compound, INE963, in the treatment of **malaria**. This study is a Phase 1 trial, which is typically the first stage of testing in human subjects. The trial will employ a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated recruitment start date is May 19, 2025, with an anticipated end date of February 11, 2026, indicating an overall trial duration of approximately nine months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation to ensure participants meet the necessary inclusion criteria and do not fall under any exclusion criteria. Following successful screening, participants will be randomly assigned to receive either the investigational compound or a control. Throughout the trial, participants will attend regular follow-up visits to monitor their health status, assess the compound's effects, and collect data on its metabolism and elimination. These visits are crucial for ensuring participant safety and gathering essential data for the study's objectives.

The end-of-study visit will mark the conclusion of a participant's involvement in the trial. During this visit, final assessments will be conducted to evaluate the long-term effects of the compound and ensure the participant's well-being. The expected length of participant involvement will vary depending on individual response and adherence to the study protocol. Conditions that may lead to early termination from the study include adverse reactions, non-compliance with study procedures, or withdrawal of consent by the participant. The trial's design and procedures are structured to maintain the highest ethical standards and scientific rigor, ensuring the collection of reliable data to inform future research and potential therapeutic applications for malaria.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of this data limits the ability to describe the treatment protocols accurately.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an initial investigation into the safety and potential efficacy of the intervention. The estimated recruitment start date is May 19, 2025, with an anticipated end date of February 11, 2026. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, Phase 1 trials typically focus on safety and dosage, with preliminary efficacy assessments often included. The trial will likely involve regular monitoring and data collection at predetermined intervals to evaluate the intervention's impact on the targeted medical condition. The analysis will be conducted using scientifically validated methods appropriate for early-phase clinical research.